Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>Canagliflozin resulted in a lower risk of cardiovascular disease in type 2 diabetics who were at high cardiovascular risk. However, there was a higher risk of amputation, which is a new finding.</p>

Canagliflozin Reduces Cardiovascular Events in Diabetic Patients